| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 19.12.25 | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 17.12.25 | Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare | 309 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| VASO Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | Vaso announces divestiture of VasoHealthcare for $0.8M | 1 | Seeking Alpha | ||
| 19.11.25 | NANO-X IMAGING LTD: Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions | 484 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties... ► Artikel lesen | |
| 14.11.25 | Vasomedical reports Q3 results | 1 | Seeking Alpha | ||
| 14.11.25 | Vaso Corporation Announces Financial Results for Third Quarter of 2025 | 280 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 02.09.25 | Telescope Innovations Corp.: Telescope Innovations Appoints Vaso Vlachos as Chief Operating Officer | 458 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a leader... ► Artikel lesen | |
| 15.05.25 | Vaso Corporation Announces Financial Results for First Quarter of 2025 | 308 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 31.03.25 | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024 | 284 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services,... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 39,065 | +2,10 % | Märkte am Morgen: Öl, Chevron, Bayer, SAP, Lanxess, Vonovia, Commerzbank | Der deutsche Aktienmarkt hat einen Handelstag der Extreme hinter sich. Die Handelsspanne beim DAX betrug gestern mehr als 1.300 Punkte. Letzten Endes schloss der Leitindex klar im Plus. Heute droht... ► Artikel lesen | |
| ASTRAZENECA | 169,00 | -0,12 % | DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf 'Sell' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 11500 Pence belassen. Die jüngsten leichten kommerziellen Rückschläge des Konkurrenten... ► Artikel lesen | |
| EYEPOINT | 10,635 | +2,90 % | EyePoint Pharmaceuticals: Strategische Fortschritte bei Netzhaut-Therapie DURAVYU auf RBC-Konferenz vorgestellt | ||
| IONIS PHARMACEUTICALS | 62,80 | -0,76 % | Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market | ||
| WAYLAND GROUP | - | - | EQS-News: Berger Montague (Canada) PC: Ankündigung der Anhörung zur Genehmigung des Vergleichs - Wayland Group Corp., Scott Langille, Gerhard Müller, Paul Pathak, Eric Silver, M. Stein, John Does 1-3, Canaccord Genuity Corp. und RF Securities Clearing LP | EQS-News: Berger Montague (Canada) PC
/ Schlagwort(e): Rechtssache/Sonstiges
ANKÜNDIGUNG DER ANHÖRUNG ZUR GENEHMIGUNG DES VERGLEICHS - KURZFASSUNG - WAYLAND... ► Artikel lesen | |
| CSPC PHARMA | 1,023 | +0,79 % | BofAS Lowers TP for CSPC Pharmaceutical to HKD7.4, Raises Gross Margin Forecast, Reiterates 'Buy' | ||
| SELLAS LIFE SCIENCES | 3,465 | -0,86 % | SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026 | ||
| CATALYST PHARMACEUTICALS | 20,480 | -1,30 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,370 | -0,14 % | Acadia Pharma upgraded at BofA following stock pullback | ||
| MADRIGAL PHARMACEUTICALS | 438,90 | +0,21 % | Madrigal Pharmaceuticals-Aktie +12%: Kommt's zur Übernahme? | Die Aktie des US-Pharmaunternehmens Madrigal Pharmaceuticals hat einen kräftigen Kurssprung verzeichnet, nachdem Spekulationen über eine mögliche Übernahme durch den Pharmariesen Eli Lilly aufkamen.... ► Artikel lesen | |
| OPUS GENETICS | 3,790 | -0,39 % | Opus Genetics, Inc.: Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 | ||
| CHUGAI PHARMACEUTICAL | 47,540 | +1,95 % | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,380 | 0,00 % | Savara Inc.: Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- EMA Review of MOLBREEVI MAA Has Now Initiated, Decision Expected in Q1 2027 -- -- MOLBREEVI Biologics License Application (BLA) is Currently Under Priority Review with the U.S. Food and Drug... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,360 | -4,84 % | Galectin Therapeutics Inc.: Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. | NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension... ► Artikel lesen |